877-272-6226
胰腺癌行动网络（PANCAN）执行团队是一群专业的专业人员，其中一些人亲自被该疾病触及，他们为美国的主要非营利组织和营利性公司带来了重要的经验和专业知识，以领导该组织。执行团队总部位于加利福尼亚州曼哈顿海滩的国家总部，以及华盛顿特区的政府事务与倡导办公室。
Julie M. Fleshman, JD, MBA
总裁兼首席执行官
In her 21 years of leadership at PanCAN, Julie Fleshman has been a global catalyst for change in the fight against pancreatic cancer. Her commitment began after she lost her dad to the disease, just four months after his diagnosis. He was 52. Fleshman wanted to know why more wasn’t being done – why her dad and thousands of other patients were offered no treatment options and sent home to die.
The pancreatic cancer landscape back then was quite different from today. Very little was known about the disease, only a handful of researchers were studying it and the five-year survival rate was just 4%.
In 1999, Fleshman was hired as PanCAN’s first employee, became its first Executive Director in 2000 and in 2004, became President and CEO.
Under her leadership, PanCAN has grown from a staff of one with annual revenues of $228,000 to a staff of over 150 with a budget of over $40 million.
Advocacy and grassroots efforts have expanded to 57 affiliates nationwide and yielded a $160 million increase in federal funding for pancreatic cancer research.
Fleshman鼓励召开的权威专家nd stakeholders in the field – researchers, healthcare professionals, industry and key opinion leaders. This allows her to build a continually expanding community of hundreds of pancreatic cancer thought leaders across the country who work in concert and devote their research efforts to improving patient outcomes.
During Fleshman’s tenure, the organization has awarded 218 pancreatic cancer research grants and has a projected total research investment of approximately $149 million, including the competitive Research Grants Program and leading-edge scientific and clinical initiatives.
Her collaborative leadership style enabled the organization to launch ground-breaking initiatives like PanCAN’s Precision PromiseSM——一个我们l trials platform designed to accelerate new treatment options for pancreatic cancer patients. In 2021, PanCAN launched the Early Detection Initiative, the largest prospective clinical trial of its kind, to create an early detection strategy for the disease.
弗雷什曼（Fleshman）受到国家媒体的专家追捧，包括《纽约时报》，CNN，PBS，头条新闻，CBS新闻和ABC新闻以及全国当地媒体。弗雷什曼（Fleshman）谈到了包括行业，患者，科学家，捐助者和志愿者在内的各种利益相关者群体，她经常与国会议员会面，讨论联邦投资在胰腺癌研究中的重要性。
弗雷什曼（Fleshman）拥有圣克拉拉大学（Santa Clara University）的JD和MBA学位，并获得了加利福尼亚大学圣塔芭芭拉（Santa Barbara）的学士学位，在那里她以优异的成绩毕业。她还在牛津大学和日本东京出国学习。
Fleshman has been honored for her leadership and dedication in the fight against pancreatic cancer by many organizations. In 2021, she was named Los Angeles Business Journal’s Nonprofit Executive of the Year. She serves on the boards of several cancer care and research committees and organizations. She recently served as a National Cancer Research Advocate for the National Cancer Institute (NCI), providing advice to the NCI Director with respect to promoting research outcomes that are in the best interest of cancer patients. She is currently a member of Clearity’s Board of Directors, a patient advocacy organization for ovarian cancer patients.
In addition, Fleshman is the Chair of the World Pancreatic Cancer Coalition, an international group of pancreatic cancer patient advocacy groups with a mission to drive transformational change for all those affected by the disease. PanCAN is a founding member of the Coalition, which includes more than 99 pancreatic cancer organizations representing 36 countries on six continents.
The pancreatic cancer landscape back then was quite different from today. Very little was known about the disease, only a handful of researchers were studying it and the five-year survival rate was just 4%.
In 1999, Fleshman was hired as PanCAN’s first employee, became its first Executive Director in 2000 and in 2004, became President and CEO.
Under her leadership, PanCAN has grown from a staff of one with annual revenues of $228,000 to a staff of over 150 with a budget of over $40 million.
Advocacy and grassroots efforts have expanded to 57 affiliates nationwide and yielded a $160 million increase in federal funding for pancreatic cancer research.
Fleshman鼓励召开的权威专家nd stakeholders in the field – researchers, healthcare professionals, industry and key opinion leaders. This allows her to build a continually expanding community of hundreds of pancreatic cancer thought leaders across the country who work in concert and devote their research efforts to improving patient outcomes.
During Fleshman’s tenure, the organization has awarded 218 pancreatic cancer research grants and has a projected total research investment of approximately $149 million, including the competitive Research Grants Program and leading-edge scientific and clinical initiatives.
Her collaborative leadership style enabled the organization to launch ground-breaking initiatives like PanCAN’s Precision PromiseSM——一个我们l trials platform designed to accelerate new treatment options for pancreatic cancer patients. In 2021, PanCAN launched the Early Detection Initiative, the largest prospective clinical trial of its kind, to create an early detection strategy for the disease.
弗雷什曼（Fleshman）受到国家媒体的专家追捧，包括《纽约时报》，CNN，PBS，头条新闻，CBS新闻和ABC新闻以及全国当地媒体。弗雷什曼（Fleshman）谈到了包括行业，患者，科学家，捐助者和志愿者在内的各种利益相关者群体，她经常与国会议员会面，讨论联邦投资在胰腺癌研究中的重要性。
弗雷什曼（Fleshman）拥有圣克拉拉大学（Santa Clara University）的JD和MBA学位，并获得了加利福尼亚大学圣塔芭芭拉（Santa Barbara）的学士学位，在那里她以优异的成绩毕业。她还在牛津大学和日本东京出国学习。
Fleshman has been honored for her leadership and dedication in the fight against pancreatic cancer by many organizations. In 2021, she was named Los Angeles Business Journal’s Nonprofit Executive of the Year. She serves on the boards of several cancer care and research committees and organizations. She recently served as a National Cancer Research Advocate for the National Cancer Institute (NCI), providing advice to the NCI Director with respect to promoting research outcomes that are in the best interest of cancer patients. She is currently a member of Clearity’s Board of Directors, a patient advocacy organization for ovarian cancer patients.
In addition, Fleshman is the Chair of the World Pancreatic Cancer Coalition, an international group of pancreatic cancer patient advocacy groups with a mission to drive transformational change for all those affected by the disease. PanCAN is a founding member of the Coalition, which includes more than 99 pancreatic cancer organizations representing 36 countries on six continents.
Pamela Acosta Marquardt
Founder
In 1996, Pamela Acosta Marquardt lost her mother to pancreatic cancer following a six-month battle. After discovering there was no organization that dealt with pancreatic cancer, Marquardt became determined to do something to ensure that patients and families had a place to turn to for information, resources and hope.
1998年11月，她通过集会并将失去亲人失去亲人的名人家庭聚集在一起，与贝弗利山庄的星星晚会一起度过了一个夜晚。晚会是有史以来首次为胰腺癌举办的重大筹款活动。活动将资助巴尔的摩的约翰霍普金斯医院的第一个早期胰腺癌的早期检测实验室。1999年2月，她创立了胰腺癌动作网络，其目标是成为对这种疾病感动的人们的希望的灯塔。
Marquardt served on the board of directors of the Pancreatic Cancer Action Network prior to joining its staff full time in 2007. A devoted advocate and tenacious leader within the pancreatic cancer community, she is also a highly regarded public speaker, regularly addressing the organization’s mission and its goal of creating a brighter future for pancreatic cancer patients.
Previously, Marquardt was Executive Director of the American Heart Association in the Inland Empire area of Southern California, where she oversaw fundraising and development. She also served in a vice president capacity in various industries, including industrial metal recycling, where she developed marketing strategies and operational systems for a leading scrap metal company, and in fashion, where she oversaw private-label management and design, as well as site procurement and store design.
1998年11月，她通过集会并将失去亲人失去亲人的名人家庭聚集在一起，与贝弗利山庄的星星晚会一起度过了一个夜晚。晚会是有史以来首次为胰腺癌举办的重大筹款活动。活动将资助巴尔的摩的约翰霍普金斯医院的第一个早期胰腺癌的早期检测实验室。1999年2月，她创立了胰腺癌动作网络，其目标是成为对这种疾病感动的人们的希望的灯塔。
Marquardt served on the board of directors of the Pancreatic Cancer Action Network prior to joining its staff full time in 2007. A devoted advocate and tenacious leader within the pancreatic cancer community, she is also a highly regarded public speaker, regularly addressing the organization’s mission and its goal of creating a brighter future for pancreatic cancer patients.
Previously, Marquardt was Executive Director of the American Heart Association in the Inland Empire area of Southern California, where she oversaw fundraising and development. She also served in a vice president capacity in various industries, including industrial metal recycling, where she developed marketing strategies and operational systems for a leading scrap metal company, and in fashion, where she oversaw private-label management and design, as well as site procurement and store design.
Sudheer Doss，博士
Chief Business Officer
Sudheer Doss博士负责与Pancan的科学和医疗计划相关的业务发展活动。多斯（Doss）监督建立行业关系，经纪人战略合作伙伴关系的团队，并管理协作计划，以推动潘卡（Pancan）的研究和临床计划向前发展。Sudheer还负责创建和执行组织的健康数据和技术策略，为Pancan的科学和医学事务计划产生的所有患者数据。
Doss previously worked as director of the precision medicine practice for PricewaterhouseCoopers (PwC). For more than a decade, he led PwC consulting engagements to develop and execute precision medicine strategies for stakeholders across the healthcare ecosystem. Doss’ educational background in science – specifically genomics and bioinformatics – and his professional experience in strategic and operational initiatives in precision medicine, make him a natural fit with PanCAN’s multitude of innovative scientific and clinical programs.
Doss is a graduate of the University of California, Los Angeles, where he received a PhD in human genetics and bioinformatics and a bachelor’s degree in microbiology and molecular genetics.
Doss previously worked as director of the precision medicine practice for PricewaterhouseCoopers (PwC). For more than a decade, he led PwC consulting engagements to develop and execute precision medicine strategies for stakeholders across the healthcare ecosystem. Doss’ educational background in science – specifically genomics and bioinformatics – and his professional experience in strategic and operational initiatives in precision medicine, make him a natural fit with PanCAN’s multitude of innovative scientific and clinical programs.
Doss is a graduate of the University of California, Los Angeles, where he received a PhD in human genetics and bioinformatics and a bachelor’s degree in microbiology and molecular genetics.
Anne-Marie Duliege, MD
Chief Medical Officer
As Chief Medical Officer for the Pancreatic Cancer Action Network, Anne-Marie Duliege, MD, is responsible for the strategic direction and operational oversight for the organization’s clinical initiatives, including PanCAN’s Precision Promise℠ clinical trial.
Duliege is a senior executive with extensive experience in the biopharmaceutical industry. Most recently, she was the Executive Vice President and Chief Medical Officer of Rigel Pharmaceuticals, where she led the development of new drugs for auto-immune diseases and got their first drug approved. She was the EVP and Chief of Strategic Development at ChemoCentryx, where she initiated a program in pancreatic cancer.
From 2004 to 2013, Duliege was VP then CMO and Head of Research and Clinical Development at Affymax. Under her leadership, her team completed an extensive development program and obtained FDA approval of the company’s lead product for anemia in dialysis patients. Prior to that, Duliege worked at Chiron and Genentech on various programs including an HIV vaccine and treatment. Prior to her career in the biopharmaceutical industry, Duliege was an epidemiologist with the National Institute of Science and Medical Research in Paris.
Duliege received her MD degree, her certification in pediatrics and a masters in biostatistics from Paris Medical School. She also holds a masters in epidemiology from the Harvard School of Public Health. She continues to practice pediatrics as an Adjunct Clinical Assistant Professor at Stanford Lucile Packard Children’s Hospital. Duliege serves on the board of CIRM, the California Institute for Regenerative Medicine, an organization focused on stem cell research. In addition, she serves on boards of nonprofits dedicated to causes such as the prevention of HIV and improving access to healthcare in developing countries.
Duliege is a senior executive with extensive experience in the biopharmaceutical industry. Most recently, she was the Executive Vice President and Chief Medical Officer of Rigel Pharmaceuticals, where she led the development of new drugs for auto-immune diseases and got their first drug approved. She was the EVP and Chief of Strategic Development at ChemoCentryx, where she initiated a program in pancreatic cancer.
From 2004 to 2013, Duliege was VP then CMO and Head of Research and Clinical Development at Affymax. Under her leadership, her team completed an extensive development program and obtained FDA approval of the company’s lead product for anemia in dialysis patients. Prior to that, Duliege worked at Chiron and Genentech on various programs including an HIV vaccine and treatment. Prior to her career in the biopharmaceutical industry, Duliege was an epidemiologist with the National Institute of Science and Medical Research in Paris.
Duliege received her MD degree, her certification in pediatrics and a masters in biostatistics from Paris Medical School. She also holds a masters in epidemiology from the Harvard School of Public Health. She continues to practice pediatrics as an Adjunct Clinical Assistant Professor at Stanford Lucile Packard Children’s Hospital. Duliege serves on the board of CIRM, the California Institute for Regenerative Medicine, an organization focused on stem cell research. In addition, she serves on boards of nonprofits dedicated to causes such as the prevention of HIV and improving access to healthcare in developing countries.
Jodi Lipe
Chief Marketing Officer
As Chief Marketing Officer for the Pancreatic Cancer Action Network, Jodi Lipe oversees marketing and communications strategies across the organization, including raising awareness and visibility about pancreatic cancer, elevating the organization’s role as the leader in the pancreatic cancer field, and ensuring a robust and diverse pipeline of constituents.
Lipe has a broad marketing and communications background in both the for-profit and nonprofit sectors. She has a proven track record in brand building, public relations, communications, revenue growth, partnership marketing and results-driven operational excellence, which is crucial for the organization’s goal to improve patient outcomes.
Previously, Lipe held executive marketing and leadership roles, both as a consultant and on staff, for a variety of high-profile entertainment, tech and nonprofit businesses including MGM, the Jewish Community Center of San Francisco, POPSUGAR, Cisco, Current TV and the Cartoon Network.
Lipe获得了新罕布什尔大学的学士学位，并在她的整个营销生涯中获得了多个奖项，包括铜牌和银色Addy奖。
Lipe has a broad marketing and communications background in both the for-profit and nonprofit sectors. She has a proven track record in brand building, public relations, communications, revenue growth, partnership marketing and results-driven operational excellence, which is crucial for the organization’s goal to improve patient outcomes.
Previously, Lipe held executive marketing and leadership roles, both as a consultant and on staff, for a variety of high-profile entertainment, tech and nonprofit businesses including MGM, the Jewish Community Center of San Francisco, POPSUGAR, Cisco, Current TV and the Cartoon Network.
Lipe获得了新罕布什尔大学的学士学位，并在她的整个营销生涯中获得了多个奖项，包括铜牌和银色Addy奖。
Lynn Matrisian博士，MBA
Chief Science Officer
As Chief Science Officer, Lynn Matrisian brings extensive experience and passion for cancer research, combined with business training, to provide strategic direction for the scientific aspects of the initiatives and activities within the Scientific & Medical Affairs team toward the goal of improving outcomes for those facing pancreatic cancer.
在加入胰腺癌动作网络之前，Matrisian将她的科学培训进行了25年的工作，领导着一项研究实验室，致力于了解癌症转移。她发表了250多种原始科学文章，并培训了30多位年轻科学家，他们继续在学术，生物技术，制药，政府和非营利部门中加入对抗癌症的斗争。
Matrisian was the founding chair of the department of cancer biology in the School of Medicine at Vanderbilt University, the president of the American Association for Cancer Research (AACR) and a special assistant to the director of the National Cancer Institute at the National Institutes of Health. She was elected to the AACR Academy, which recognizes and honors distinguished scientists whose major scientific contributions have propelled significant innovation and progress against cancer.
Matrisian获得了亚利桑那大学的分子生物学博士学位，并获得了范德比尔特大学欧文管理研究生院的MBA学位。
在加入胰腺癌动作网络之前，Matrisian将她的科学培训进行了25年的工作，领导着一项研究实验室，致力于了解癌症转移。她发表了250多种原始科学文章，并培训了30多位年轻科学家，他们继续在学术，生物技术，制药，政府和非营利部门中加入对抗癌症的斗争。
Matrisian was the founding chair of the department of cancer biology in the School of Medicine at Vanderbilt University, the president of the American Association for Cancer Research (AACR) and a special assistant to the director of the National Cancer Institute at the National Institutes of Health. She was elected to the AACR Academy, which recognizes and honors distinguished scientists whose major scientific contributions have propelled significant innovation and progress against cancer.
Matrisian获得了亚利桑那大学的分子生物学博士学位，并获得了范德比尔特大学欧文管理研究生院的MBA学位。
Edwina Mossett，SPHR，SHRM-SCP
Chief People Officer
As Chief People Officer, Edwina Mossett is responsible for leading the strategy, development and execution of all human resources programs and people initiatives for the Pancreatic Cancer Action Network.
Mossett is a seasoned human resources professional with more than 20 years of executive leadership experience in fast-growing, high-energy, creative and emerging industries. Her specialty is building and scaling world-class cultures and organizations. She most recently served as Vice President, People Business Partner at Beachbody, LLC. Her background also includes several years as Senior Vice President of Human Capital at Spectrum Athletic Clubs, as well as Vice President of Human Resources & Administration for Applied Minds and Virgin Records America.
Mossett拥有Biola大学的工商管理学士学位，并参加了Pepperdine University的执行MBA课程。她持有SPHR和SHRM-SCP证书，宾夕法尼亚大学沃顿大学的战略管理证书以及长滩加利福尼亚州立大学的人力资源发展证书。
Mossett is a seasoned human resources professional with more than 20 years of executive leadership experience in fast-growing, high-energy, creative and emerging industries. Her specialty is building and scaling world-class cultures and organizations. She most recently served as Vice President, People Business Partner at Beachbody, LLC. Her background also includes several years as Senior Vice President of Human Capital at Spectrum Athletic Clubs, as well as Vice President of Human Resources & Administration for Applied Minds and Virgin Records America.
Mossett拥有Biola大学的工商管理学士学位，并参加了Pepperdine University的执行MBA课程。她持有SPHR和SHRM-SCP证书，宾夕法尼亚大学沃顿大学的战略管理证书以及长滩加利福尼亚州立大学的人力资源发展证书。
Lori Stevens
Chief Development and Community Engagement Officer
As Chief Development and Community Engagement Officer for the Pancreatic Cancer Action Network, Lori Stevens drives strategy, management, leadership and implementation of the organization’s fundraising efforts and volunteer engagement activities.
She brings extensive nonprofit and corporate sales experience to the role, along with a successful track record in revenue growth, strategic planning, team management and special event execution.
Most recently Lori served as Senior Vice President for the Western States Affiliate of the American Heart Association, where she was responsible for Division revenue and mission impact in alignment with both affiliate and national goals and priorities.
史蒂文斯还曾担任美国糖尿病协会（ADA）西部部门现场运营副总裁八年，收入为3,300万美元。在ADA任职的20年期间，她从区域公司发展总监担任高级执行总监的渐进式职务。史蒂文斯（Stevens）拥有南加州大学的工商管理学士学位。
She brings extensive nonprofit and corporate sales experience to the role, along with a successful track record in revenue growth, strategic planning, team management and special event execution.
Most recently Lori served as Senior Vice President for the Western States Affiliate of the American Heart Association, where she was responsible for Division revenue and mission impact in alignment with both affiliate and national goals and priorities.
史蒂文斯还曾担任美国糖尿病协会（ADA）西部部门现场运营副总裁八年，收入为3,300万美元。在ADA任职的20年期间，她从区域公司发展总监担任高级执行总监的渐进式职务。史蒂文斯（Stevens）拥有南加州大学的工商管理学士学位。
Placeholder
